The effect of romosozumab on bone mineral density depending on prior treatment: a prospective, multicentre cohort study in Switzerland

Osteoporos Int. 2024 Sep;35(9):1605-1613. doi: 10.1007/s00198-024-07155-9. Epub 2024 Jun 26.

Abstract

This multicentre, prospective cohort study measured the effect of romosozumab for 12 months on bone mineral density, taking into account prior therapies. Prior antiresorptive therapy blunted the BMD response to romosozumab, and the duration was correlated with BMD changes at both the lumbar spine and total hip.

Introduction: In Switzerland, romosozumab is administered to high-risk osteoporosis patients. Our study aimed to assess the effect of romosozumab on bone mineral density (BMD), taking into account prior therapies.

Methods: This multicentre, prospective cohort study measured the effect of romosozumab for 12 months in patients in a nationwide Swiss osteoporosis registry. BMD and bone turnover marker (P1NP and CTX) changes were measured and compared between pre-treated and treatment naïve patients.

Results: Ninety-nine patients (92 women and 7 men, median age 71 years [65, 76]) were enrolled from January 2021 to December 2023. Among them, 22 had no prior treatment before romosozumab, while 77 had previous therapy (including 23 with a history of prior teriparatide therapy), with a median duration of 6 years [4, 11] of cumulative antiresorptive treatment. Over 12 months, romosozumab led to BMD changes of 10.3% [7.5, 15.5] at the lumbar spine, 3.1% [1.1, 5.8] at the total hip and 3.1% [0.5, 5.3] at the femoral neck, indicating notable variability. Significantly lower BMD responses were observed in pre-treated patients, with the duration of prior antiresorptive therapy inversely associated with BMD increases at the lumbar spine and hip. Other predictors of BMD changes at the total hip included baseline T-scores at the hip, body mass index and baseline CTX level, while the BMD response at the lumbar spine was associated with the lumbar spine T-score at baseline, age and baseline CTX level.

Conclusion: Prior antiresorptive therapy blunted the BMD response to romosozumab, and the duration was correlated with BMD changes at both the lumbar spine and total hip.

Keywords: Bone mineral density; Fractures; Osteoporosis; Romosozumab.

Publication types

  • Multicenter Study

MeSH terms

  • Absorptiometry, Photon / methods
  • Aged
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use
  • Biomarkers / blood
  • Bone Density Conservation Agents* / administration & dosage
  • Bone Density Conservation Agents* / pharmacology
  • Bone Density Conservation Agents* / therapeutic use
  • Bone Density* / drug effects
  • Bone Density* / physiology
  • Bone Remodeling / drug effects
  • Bone Remodeling / physiology
  • Collagen Type I / blood
  • Female
  • Femur Neck / physiopathology
  • Hip Joint / physiopathology
  • Humans
  • Lumbar Vertebrae* / physiopathology
  • Male
  • Osteoporosis* / drug therapy
  • Osteoporosis* / physiopathology
  • Peptide Fragments / blood
  • Peptides
  • Procollagen / blood
  • Prospective Studies
  • Registries
  • Switzerland

Substances

  • Bone Density Conservation Agents
  • romosozumab
  • Antibodies, Monoclonal
  • Biomarkers
  • Procollagen
  • procollagen Type I N-terminal peptide
  • Peptide Fragments
  • collagen type I trimeric cross-linked peptide
  • Collagen Type I
  • Peptides